Nathan Pennell: 3 Questions That Matter for the Next Multiple Myeloma Treatment
Nathan Pennell, Senior Vice President, Head of Global Medical Oncology at Bristol Myers Squibb, shared a post on LinkedIn:
“Years in the clinic have taught me to ask three questions about every new treatment:
- How well does it work?
- What does the safety profile look like?
- How can we work to make sure it reaches the patients who need it?
The Phase 3 EXCALIBER-RRMM results presented at IMS26 today give me real reason for optimism on all three counts. I’m genuinely excited by what they could mean for patients with relapsed/refractory multiple myeloma.
Having spent years working toward a future where more patients actually receive the medicines they need, I couldn’t be prouder to be part of a team accelerating the journey from scientific discovery to patient impact.
Thank you to the colleagues, investigators and patients advancing this critical research.”
Stay updated with Hemostasis Today.
-
Nov 13, 2026, 03:21Abdul Muqtadir Abbasi: Iron Deficiency Beyond Anemia and the Importance of Finding the Cause
-
Nov 13, 2026, 03:05Marc Carrier: Aspirin vs Anticoagulants for VTE Prevention After Joint Replacement
-
Nov 13, 2026, 02:28Julia Sjöberg: ROCK1 Inhibition and Red Blood Cell Recovery After Chemotherapy
-
Nov 13, 2026, 02:07Tonie Reincke: Understanding Deep Vein Thrombosis and Vascular Health
-
Nov 13, 2026, 01:52Akshita Singh: The Remarkable Process of Blood Clotting
-
Nov 12, 2026, 22:52Milka Koupenova: The Role of Platelet RIG-I in Regulating Thrombotic Responses
-
Nov 12, 2026, 22:50Arun V J: Why Has India Still Not Achieved 100% Voluntary Blood Donation?
-
Nov 12, 2026, 22:49Sickle Cell Disease Deserves to Be Prioritised in Ghana – ISCC
-
Nov 12, 2026, 22:47Samir Kumar Beura: Delighted to Serve as a Topic Editor for a Research Topic in Frontiers in Neuroscience